The Gross Law Firm has announced a class action lawsuit for shareholders of Replimune Group, Inc. who bought shares between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made false or misleading statements about its FDA Biologics License Application (BLA), including failure to address FDA concerns and reliance on limited early data from a small patient group. These issues may have led to an artificial inflation of the company's stock price. Shareholders can register by October 5, 2026, to participate or seek lead plaintiff status at no cost.
Grocery Outlet Holding Corp. reported a 1.1% revenue increase to $1.19 billion in Q2 2026 and an adjusted EPS of $0.20, beating analyst expectations despite a 13% EPS decline. The company is undergoing strategic restructuring, including closing 36 un...
Hesai Group reported Q2 2026 earnings with revenue of $126.9 million, slightly above expectations, driven by strong LiDAR sales. Despite an EPS of $0.01 missing the $0.08 estimate, the company achieved its fifth consecutive GAAP profitable quarter, w...
Amylyx Pharmaceuticals' stock surged 54.43% after its drug avexitide showed positive Phase 3 trial results, cutting hypoglycemic events by 55% in post-bariatric patients. UBS set a $45 price target, implying a 36% upside from current levels. The stoc...
Ondas is expanding its market and technology through acquiring Aran Defense Ltd., enhancing its autonomous and defense systems. The company reported record Q2 revenue of $83.8 million, up 67% from the previous quarter and over 13 times year-over-year...
Xiaomi Corp reported better-than-expected earnings per share of $0.05 and revenue of $16.04 billion, surpassing analyst forecasts. However, the company faces significant margin pressure from rising component costs and weaker consumer demand, causing ...
